246 related articles for article (PubMed ID: 10343002)
1. Current issues in the pioneer versus generic drug wars.
Safir PO
Food Drug Law J; 1995; 50(2):335-9. PubMed ID: 10343002
[No Abstract] [Full Text] [Related]
2. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
Lewis RA
J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987
[No Abstract] [Full Text] [Related]
3. Pharmaceutical patent settlements: the antitrust risks.
Balto DA
Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
[No Abstract] [Full Text] [Related]
4. Therapeutic-class wars--drug promotion in a competitive marketplace.
Kessler DA; Rose JL; Temple RJ; Schapiro R; Griffin JP
N Engl J Med; 1994 Nov; 331(20):1350-3. PubMed ID: 7935706
[No Abstract] [Full Text] [Related]
5. Generic drug purchasing.
Mehl B
Hosp Pharm; 1988 Feb; 23(2):162-4 contd. PubMed ID: 10286432
[No Abstract] [Full Text] [Related]
6. Generic vs. brand name drugs--quality, not cost, is key issue.
Stetler CJ
Internist; 1979 May; 20(4):9-10, 12. PubMed ID: 10242133
[No Abstract] [Full Text] [Related]
7. New York's generic drug substitution law.
Kamen A
N Y State Dent J; 1980 Nov; 46(9):599-604. PubMed ID: 6935574
[No Abstract] [Full Text] [Related]
8. FDA takes action against firms in scandal over generic products.
Pollner F
Med World News; 1989 Sep; 30(17):14-5. PubMed ID: 10294736
[No Abstract] [Full Text] [Related]
9. Status of generic substitution: problematic drug classes reviewed.
Ross MB
Hosp Formul; 1989 Aug; 24(8):441-4, 447-9. PubMed ID: 10294356
[TBL] [Abstract][Full Text] [Related]
10. The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality?
Marsh DA; Hoar ME
Contemp Pharm Pract; 1982; 5(2):130-5. PubMed ID: 10317245
[TBL] [Abstract][Full Text] [Related]
11. Initial responses to recommendations of the Blue Ribbon Committee on Generic Medicines.
Heller WM
Am J Hosp Pharm; 1993 Feb; 50(2):318-22. PubMed ID: 8480792
[No Abstract] [Full Text] [Related]
12. United States Food and Drug Administration requirements for approval of generic drug products.
Meyer MC
J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
[TBL] [Abstract][Full Text] [Related]
13. DPS--the PMA perspective.
Beary JF; Cleveland CB
Am Pharm; 1992 May; NS32(5):6, 8. PubMed ID: 1590210
[No Abstract] [Full Text] [Related]
14. Comparison of the bioequivalence of generic versus branded clozapine.
Ereshefsky L; Glazer WM
J Clin Psychiatry; 2001; 62 Suppl 5():25-7. PubMed ID: 11305845
[No Abstract] [Full Text] [Related]
15. The Hatch-Waxman Act: balancing competing interests or survival of the fittest?
Behrendt KE
Food Drug Law J; 2002; 57(2):247-71. PubMed ID: 12436990
[No Abstract] [Full Text] [Related]
16. Look-alike drugs and unfair competition. An update of Inwood Laboratories v. Ives Laboratories.
Shapiro LJ
Am Pharm; 1985 Oct; NS25(10):49-50. PubMed ID: 4061279
[No Abstract] [Full Text] [Related]
17. Generic and alternative brand-name pharmaceutical equivalents: select with caution.
Hendeles L; Hochhaus G; Kazerounian S
Am J Hosp Pharm; 1993 Feb; 50(2):323-9. PubMed ID: 8480793
[No Abstract] [Full Text] [Related]
18. Generic substitution: issues for problematic drugs.
Henderson JD; Esham RH
South Med J; 2001 Jan; 94(1):16-21. PubMed ID: 11213935
[TBL] [Abstract][Full Text] [Related]
19. Pharmacist compounding of analgesic medication: the risk of a little-known practice.
Johnson P; Jones G
J Fla Med Assoc; 1997 Jan; 84(1):13-5. PubMed ID: 9037992
[No Abstract] [Full Text] [Related]
20. Repercussions of the Drug Price Competition and Patent Term Restoration Act of 1984.
Hogan GF
Am J Hosp Pharm; 1985 Apr; 42(4):849-51. PubMed ID: 4014238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
